bioAffinity Technologies, Inc.
BIAF
$0.475
-$0.024-4.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.21M | 2.35M | 2.40M | 2.41M | 2.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.21M | 2.35M | 2.40M | 2.41M | 2.21M |
| Cost of Revenue | 1.56M | 1.44M | 1.41M | 1.57M | 1.66M |
| Gross Profit | 645.40K | 910.20K | 989.90K | 833.00K | 548.50K |
| SG&A Expenses | 2.92M | 2.36M | 2.47M | 2.19M | 2.21M |
| Depreciation & Amortization | 153.60K | 151.30K | 151.10K | 149.60K | 148.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.15M | 4.32M | 4.49M | 4.35M | 4.56M |
| Operating Income | -2.95M | -1.97M | -2.09M | -1.95M | -2.34M |
| Income Before Tax | -2.97M | -2.00M | -2.10M | -1.96M | -2.37M |
| Income Tax Expenses | 0.00 | 2.60K | 5.40K | 3.70K | 2.30K |
| Earnings from Continuing Operations | -2.97M | -2.00M | -2.11M | -1.96M | -2.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.97M | -2.00M | -2.11M | -1.96M | -2.37M |
| EBIT | -2.95M | -1.97M | -2.09M | -1.95M | -2.34M |
| EBITDA | -2.79M | -1.82M | -1.94M | -1.80M | -2.19M |
| EPS Basic | -0.20 | -0.16 | -0.19 | -0.20 | -0.25 |
| Normalized Basic EPS | -0.13 | -0.10 | -0.12 | -0.12 | -0.16 |
| EPS Diluted | -0.20 | -0.16 | -0.19 | -0.20 | -0.25 |
| Normalized Diluted EPS | -0.13 | -0.10 | -0.12 | -0.12 | -0.16 |
| Average Basic Shares Outstanding | 14.79M | 12.39M | 11.39M | 9.92M | 9.34M |
| Average Diluted Shares Outstanding | 14.79M | 12.39M | 11.39M | 9.92M | 9.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |